Related by context. All words. (Click for frequent words.) 77 Phase IIa trial 76 Phase 2a trial 75 Phase 2b study 75 Phase IIb trial 75 phase IIb 75 phase IIb trial 75 phase IIa clinical 75 phase IIb clinical 75 phase IIa 74 Phase Ib clinical 74 GALNS 74 Phase Ib 74 Phase III trials 74 Phase Ib study 74 registrational trial 74 Phase IIb clinical 74 Phase 2b trial 74 Phase 2a clinical trials 73 forodesine 73 Phase 2a clinical 73 INCB# [001] 73 Phase IIa clinical trials 73 Phase IIb clinical trials 73 Phase 2a 72 Phase IIa trials 72 Phase 1b trial 72 Plicera 72 Phase Ib II 72 confirmatory Phase III 72 Phase 2b clinical trials 72 phase IIb study 72 Phase IIIb clinical 71 multicenter Phase 71 IIa trial 71 Phase III clinical trials 70 Phase 1b clinical 70 phase Ib 70 PANVAC VF 70 Phase IIb 70 rALLy clinical trial 70 dirucotide 70 Phase IIa clinical 70 Phase #b/#a clinical 70 Phase 2b clinical 70 Phase Ib clinical trials 70 phase Ib clinical 70 mGluR5 negative 70 Phase 1b 70 alvespimycin 69 phase 2a 69 deforolimus 69 cannabinor 69 vidofludimus 69 Phase 1a clinical 69 elotuzumab 69 Phase IIa 69 registrational 69 TELINTRA 69 antibody MAb 69 generation purine nucleoside 69 Phase III clinical 69 Phase IIB 69 PRT# 69 initiate Phase IIb 69 oral ridaforolimus 69 TLK# 69 CUSTOM III 69 huC# DM4 69 Phase IIb Clinical Trial 69 ocrelizumab 69 Phase IIb Trial 68 lintuzumab SGN 68 BLA filing 68 PNP inhibitor 68 RhuDex ® 68 PDE4 inhibitor 68 JAK inhibitor 68 PSN# [002] 68 Troxatyl 68 dose escalation Phase 68 midstage trials 68 Phase #b/#a 68 virus HCV protease inhibitor 68 Phase Ib IIa 68 Personalized Immunotherapy 68 pivotal Phase III 68 CB2 selective receptor agonist 68 CR# vcMMAE 68 HGS# 68 Fx #A 68 Bezielle 68 Archexin 68 Pivotal Phase III 68 ruxolitinib 68 AEG# 68 axitinib 68 PRX # 68 Phase 1a 68 Bicifadine 68 lomitapide 68 IMA# 68 Initiate Phase 68 mertansine 68 octreotide implant 68 bicifadine 68 IL# PE#QQR 68 PEG PAL 68 Nuvion 68 Quinamed 68 Panzem R NCD 68 receptor tyrosine kinase inhibitor 68 initiate Phase 2b 68 Telintra 68 SUCCEED trial 67 MAA submission 67 placebo controlled Phase 67 Phase III 67 Vitaxin 67 Laquinimod 67 Dacogen injection 67 Ozarelix 67 APEX PD 67 otelixizumab 67 Ocrelizumab 67 midstage studies 67 Phase III Clinical Trials 67 Phase #/#a trial 67 TBC# 67 Phase 2b Clinical Trial 67 brivaracetam 67 SinuNase TM 67 TOCOSOL Paclitaxel 67 Elagolix 67 Pivotal Phase 67 oral prodrug 67 huN# DM1 67 TASKi2 67 confirmatory Phase 3 67 multicenter Phase II 67 Phase Ia 67 IMC A# 67 NGX# 67 eniluracil 67 Allovectin 7 67 Panzem R 67 CD# CEA 67 IMC #B 67 PF # [002] 67 Phase 1b clinical trials 67 Allovectin 7 R 67 JAK1 67 Corlux 67 dose cohort 67 ProSavin 67 MAGE A3 ASCI 67 IND submission 67 investigational humanized monoclonal antibody 67 LymphoStat B belimumab 67 pertuzumab 67 bosutinib 67 randomized Phase IIb 67 AQ4N 67 MBP# [001] 67 Phase 2b 67 compound INCB# 67 MAXY alpha 66 reslizumab 66 BENLYSTA TM 66 Phase 2b Trial 66 HGS ETR1 66 oral methylnaltrexone 66 Phase III Pivotal 66 MGCD# [001] 66 HuMax EGFr 66 clinical pharmacology studies 66 confirmatory pivotal 66 AZILECT R 66 Alzhemed TM 66 Vicriviroc 66 TACI Ig 66 SAR# [004] 66 pradefovir 66 Phenoptin 66 FOLOTYN ® 66 BRIM2 66 TRO# 66 OvaRex R 66 Phase #/#a 66 docetaxel Taxotere R 66 tramiprosate Alzhemed TM 66 cathepsin K inhibitor 66 Factor VIIa 66 CCR9 antagonist 66 PRECISE trial 66 PEG SN# 66 AIMM trial 66 BRIM3 66 Mipomersen 66 Fibrillex TM 66 CCR5 antagonist 66 RhuDex TM 66 Asentar 66 NVA# 66 R#/MEM # 66 Amigal 66 inhaled formulation 66 IND enabling 66 pivotal Phase 66 seliciclib CYC# 66 Phase IIIb 66 SinuNase ™ 66 mGluR2 positive 66 severe hypercholesterolemia 66 Phase #b/#a trial 66 ATHX 66 dosing cohorts 66 tiapamil 66 Cloretazine ® 65 Traficet EN 65 PRTX 65 GLPG# 65 MKC# MT 65 AEGR 65 incyclinide 65 Aurora kinase inhibitor 65 Pimavanserin 65 Viramidine 65 JZP 65 alemtuzumab Campath 65 II Clinical Trial 65 metastatic hormone refractory 65 midstage clinical 65 placebo controlled clinical 65 Meets Primary Endpoint 65 HCV SPRINT 65 RSD# oral 65 Serdaxin 65 ganetespib 65 dose cohorts 65 REVIVE Diabetes 65 Xanafide 65 dose escalation trial 65 Phase III Clinical Trial 65 EDEMA3 65 clinical trials 65 dosing cohort 65 ofatumumab HuMax CD# 65 AAG geldanamycin analog 65 GLP toxicology studies 65 Phase III Trial 65 bardoxolone 65 talactoferrin 65 CTAP# Capsules 65 diabetic neuropathic pain 65 investigational compound 65 Tasimelteon 65 TELCYTA 65 tezampanel NGX# 65 TKB# 65 tezampanel 65 elacytarabine 65 HuMax CD# 65 PXD# 65 BAY #-# 65 PFO migraine 65 APTIVUS 65 visilizumab 65 Cetrorelix 65 BCX# 65 ACTEMRA TM 65 JAK2 inhibitor 65 torezolid phosphate 65 multiple ascending dose 65 OvaRex ® MAb 65 diarrhea predominant irritable 65 zanolimumab 65 Zenvia ™ 65 nucleotide analog 65 non nucleoside inhibitor 65 HCD# [002] 65 PD LID 65 sunitinib malate 65 tanespimycin 65 oxymorphone ER 65 Cethromycin 65 Zenvia Phase III 65 Completes Patient Enrollment 65 apricitabine ATC 65 CytoFabTM 65 cetuximab Erbitux 65 evaluating tivozanib 65 AZILECT ® 65 Combination REOLYSIN R 65 PEGylated interferon beta 1a 65 Pivotal Trial 65 Safinamide 65 tremelimumab 65 pharmacokinetic PK study 65 GRN# 65 Zybrestat 65 investigational monoclonal antibody 65 Testosterone MDTS ® 65 Diamyd ® 65 Tezampanel 65 Phase III pivotal 65 Aflibercept 65 acyclovir Lauriad R 65 Ophena TM 65 Achieves Primary Endpoint 65 ATL# [001] 65 OMNARIS Nasal Spray 65 Reverset 65 CCX# B 65 trastuzumab DM1 T DM1 65 dasatinib Sprycel ® 65 rindopepimut 65 hypoxia activated prodrug 65 OncoGel 65 Triolex 65 beta 1a 65 TMC# [002] 65 fostamatinib 65 Sapacitabine 65 Successfully Completes Phase 65 cystinosis patients 65 Urocidin 65 enzastaurin 65 CRMD# 65 ANCHOR trial 65 SPRYCEL ® 65 omega interferon 65 rALLy trial 65 Fodosine 65 Myelodysplastic Syndrome MDS 64 opioid induced bowel dysfunction 64 GAMMAGARD 64 budesonide foam 64 nalbuphine ER 64 dextromethorphan quinidine 64 Omacetaxine 64 Ixempra 64 Randomized Phase 64 R# #mg BID 64 Preclinical studies suggest 64 Exherin TM 64 Begins Dosing 64 tolevamer 64 CHAMPION PCI 64 HCV RESPOND 2 64 initiated Phase Ib 64 generation NNRTI 64 MEK inhibitor RDEA# 64 ELACYT 64 including eniluracil ADH 64 MNTX 64 daclizumab 64 IIa clinical trial 64 urocortin 2 64 administered subcutaneously 64 lintuzumab 64 cetuximab Erbitux R 64 Proxinium TM 64 drug pipeline TAFA# 64 Clavis Pharma 64 randomized Phase 2b 64 KRN# 64 PROMACTA 64 Silodosin 64 Copegus ribavirin 64 glucokinase activator 64 intranasal formulation 64 HuMax CD4 64 ONCONASE R 64 Glufosfamide 64 Cannabinor 64 allosteric modulator NAM 64 LY# [003] 64 phase IIIb 64 SNT MC# 64 MERLIN TIMI 64 orally administered inhibitor 64 IRX 2 64 NOX E# 64 Ostarine 64 Inc. Nasdaq VVUS 64 Firazyr 64 CDP# 64 IIb clinical trial 64 RhuDex 64 baminercept 64 Ceflatonin 64 anticancer compound 64 Phase 2a Clinical Trial 64 Luveniq 64 investigational protease inhibitor 64 albiglutide 64 dyskinesia PD LID 64 LAF# 64 measurable tumor regressions 64 Microplasmin 64 EndoTAG TM -1 64 nonclinical studies 64 Alocrest 64 teriflunomide 64 refractory gout 64 LEUKINE 64 pomalidomide 64 Genasense ® oblimersen 64 PEGylated Fab fragment 64 Allovectin 7 ® 64 Phase III confirmatory 64 Initiates Phase II 64 assessing T DM1 64 initiate Phase 1b 64 trabedersen 64 nitazoxanide 64 liposomal formulation 64 CRD5 64 targeted radiotherapeutic 64 Immunotherapeutic 64 DermaVir Patch 64 MEK inhibitor 64 LymphoStat B TM 64 PROVENGE sipuleucel T 64 Annamycin 64 PRECISE Trial 64 dexanabinol 64 omacetaxine mepesuccinate 64 PSMA ADC 64 YONDELIS 64 Aryplase 64 GSK# [002] 64 Icatibant 64 metastatic castration resistant 64 Civacir 64 Ridaforolimus 64 CRLX# 64 isoform selective 64 MIRCERA 64 LE SN# 64 MEND CABG 64 dose escalation clinical 64 AGILECT R 64 cutaneous T 64 novel VDA molecule 64 Glybera 64 Phase III placebo controlled 64 ospemifene 64 Locteron ® 64 Marqibo 64 MDS AML 64 Sym# 64 confirmatory clinical 64 Dextofisopam 64 telaprevir VX 64 vosaroxin 64 UPLYSO 64 metastatic renal cell 64 alvimopan 64 ulimorelin 64 Genz # 64 Onalta ™ 64 Lu AA# 64 Phase III HEAT 64 maximally tolerated dose 64 TKM ApoB 64 Tarceva TM 64 Torisel 63 riociguat 63 ZYBRESTAT 63 MIST II 63 metastatic malignant 63 PHX# 63 MKC# MKC# PP 63 lumiliximab 63 GW# [003] 63 relapsed refractory multiple myeloma 63 metastatic sarcomas 63 NASDAQ LGND 63 arzoxifene 63 selective androgen receptor modulator 63 Nasdaq HALO 63 Nexavar sorafenib 63 polymerase inhibitor 63 olaparib 63 HspE7 63 glufosfamide 63 teduglutide 63 randomized controlled Phase 63 Insegia 63 ZOLINZA 63 multi kinase inhibitor 63 integrase inhibitor 63 Memryte 63 IAP inhibitor 63 Pirfenidone 63 RG# [001] 63 EOquin 63 volociximab 63 PEG IFN 63 Campath alemtuzumab 63 refractory chronic lymphocytic 63 Tolerx 63 pharmacokinetic studies 63 2 methoxyestradiol 63 ruboxistaurin 63 Cimzia TM 63 Alemtuzumab 63 R#/MEM 63 XL# XL# XL# XL# 63 sitaxsentan 63 polycythemia vera essential thrombocythemia 63 Phase III Trials 63 PRE SURGE 63 PDE# inhibitors 63 VIRAMUNE XR 63 tivozanib 63 oral rivaroxaban 63 #D#C# 63 Desmoteplase 63 ozarelix 63 HQK 63 HDAC Inhibitor 63 TRACON Pharmaceuticals 63 Spiegelmer ® 63 custirsen 63 ARDIS 63 oral salmon calcitonin 63 dose escalation 63 Intravenous CP 63 Tovaxin ® 63 metaglidasen 63 GOUT 63 LUX Lung 63 subcutaneous formulation 63 Phase III ALLEGRO 63 liprotamase 63 trial evaluating PRX# 63 treatment naive genotype 63 histone deacetylase HDAC inhibitor 63 lorvotuzumab mertansine 63 oral deforolimus 63 oral FTY# 63 APPRAISE 63 HGS ETR2 63 bevirimat Study 63 selective modulator 63 MBP# dirucotide 63 Valtropin 63 cangrelor 63 ocular formulation 63 Surfaxin LS 63 evaluating Actimmune 63 docetaxel Taxotere ® 63 Clevudine 63 TRX1 63 generation PNP inhibitor 63 TEMSO 63 LEP ETU 63 eprotirome 63 CoFactor 63 Prodarsan ® 63 AMEVIVE 63 QNEXA 63 registrational studies 63 GLYX 63 preclinical studies 63 Prodarsan R 63 Azedra TM 63 Phase IIb III 63 RezularTM 63 ponatinib 63 EOquin TM 63 EFAPROXYN 63 ENRICH trial 63 blinded randomized placebo controlled 63 TAXUS Element Stent System 63 PROSTVAC ® 63 humanized interleukin 6 63 stated Michelle Berrey 63 ILUVIEN ® 63 mGluR5 NAM 63 randomized Phase III 63 Phase II 63 AeroLEF TM 63 PA# [002] 63 THR beta agonist 63 multicenter phase 63 DPX Survivac 63 ALN PCS 63 adalimumab Humira 63 rasagiline tablets 63 Ceflatonin R 63 evaluating satraplatin 63 cell lymphoma CTCL 63 Initiates Phase III 63 GetGoal Phase III 63 LymphoStat B 63 E1 INT TM 63 XmAb# 63 Urocortin 2 63 Prestara 63 Clonicel 63 DEB# 63 immunomodulatory therapy 63 StemEx 63 LibiGel ® 63 sapacitabine 63 QLT# 63 Capesaris 63 AVASTIN 63 carcinogenicity study 63 OHR/AVR# 63 Pharmacokinetics PK 63 PLK1 SNALP 63 plasma kallikrein inhibitor 63 AzaSite Plus 63 T Pred 63 DPP4 inhibitor 63 Tavocept 63 Brentuximab Vedotin SGN 63 Xcellerated T Cells 63 aurora kinase 63 TransVax TM 63 DU #b 63 MEND CABG II 63 albinterferon alfa 2b 63 placebo controlled Phase III 63 Kamada AAT 63 CLARITY study 63 BENLYSTA ™ 63 celgosivir 63 valopicitabine 63 Initiates Clinical 63 dasatinib Sprycel 63 Vectibix panitumumab 63 Biopharmaceuticals AG 63 Pafuramidine 63 MGd 63 Cleviprex TM clevidipine 63 Tyrima 63 Hematide ™ 63 ADVANCE PD 63 fosbretabulin 63 Initiates Enrollment 63 randomized Phase 63 DDP# 63 Octreolin 63 PS# [001] 63 Phase III randomized controlled 63 Presents Preclinical 63 Entereg R 63 XL# anticancer compounds 63 induced macular edema 63 generation proteasome inhibitor 63 CEQ# 63 Itopride 63 Rebif ® 63 candidate AQ4N 63 Daclizumab 63 IIa clinical 63 Anturol TM 63 TroVax ® 63 eltrombopag 63 satraplatin Phase 63 generation antisense inhibitor 63 ADP receptor antagonist 63 faropenem medoxomil 62 CA9 SCAN 62 Neuvenge 62 Apoptone 62 preclinically 62 First Patient Dosed 62 SPIRIT FIRST 62 entinostat 62 ANAVEX #-# [003] 62 ORENCIA R 62 MT#/MEDI-# 62 atacicept 62 Phase IIIb study 62 triphendiol 62 Telatinib 62 elagolix 62 Vascular Disrupting Agent 62 SUTENT 62 dirucotide MBP# 62 rALLy 62 human IgG1 monoclonal 62 edoxaban 62 Friedreich Ataxia FRDA 62 Phase 2a Trial 62 Dose Ranging Study 62 Ambrisentan 62 Amplimexon 62 #mg dose [002] 62 Phase Ib Clinical Trial 62 Lisofylline LSF 62 Clolar ® 62 HuLuc# 62 motesanib 62 personalized immunotherapy 62 class mGluR5 inhibitor 62 PREOS 62 ELND# 62 clinical trial 62 Pivotal Study 62 PTK ZK 62 investigational compounds 62 OMAPRO 62 neratinib 62 Symadex 62 Zalbin 62 Pruvel 62 inhibitor RG# 62 orally bioavailable 62 Tesmilifene 62 NYSE Amex PTN 62 INT# [002] 62 TMC# C# 62 trodusquemine 62 TG# [003] 62 FACTIVE tablets 62 Zingo TM 62 NO# [002] 62 Altastaph 62 EVIZON TM 62 SNT-MC#/idebenone 62 EDEMA3 trial 62 KSP inhibitor 62 sodium glucose cotransporter 62 leukemia AML 62 Inhalation Solution 62 PRIMO CABG 62 controlled multicenter Phase 62 Tanespimycin 62 preclinical 62 MCSP respectively 62 TO AVOID PREGNANCY WHILE 62 Azilect ® 62 OMNARIS HFA 62 safinamide 62 Hedgehog antagonist 62 velafermin 62 Tocosol Paclitaxel 62 NASDAQ CXSP announced 62 Hsp# Inhibitor 62 docetaxel chemotherapy 62 Cyclacel Pharmaceuticals 62 Darusentan 62 ularitide 62 Carfilzomib 62 nab paclitaxel 62 Romiplostim 62 TRIOLEX 62 Phase 1b Clinical Trial 62 Kiadis Pharma 62 Zerenex 62 PHASE III 62 allosteric modulator PAM 62 Parkinson disease levodopa induced 62 KIACTA ™ 62 NP2 Enkephalin 62 pediatric Crohn disease 62 apremilast 62 ATL/TV# 62 multicenter randomized placebo controlled 62 hyperphenylalaninemia HPA due 62 Pazopanib 62 chronic eosinophilic leukemia 62 candidates Dyloject TM 62 Myocet 62 molecular imaging radiopharmaceutical 62 pivotal bioequivalence 62 laquinimod 62 canakinumab 62 PDX pralatrexate 62 Zoraxel 62 Aurexis 62 INCB# [002] 62 dimebon latrepirdine 62 refractory CLL 62 ThGRF 62 brivanib 62 ritonavir boosted danoprevir 62 FTY# fingolimod 62 Nasdaq OPTR 62 ALN TTR# 62 dexpramipexole 62 pediatric acute lymphoblastic 62 leading oral taxane 62 GED aPC 62 sorafenib Nexavar 62 IMGN# 62 panitumumab Vectibix 62 obatoclax 62 mifamurtide 62 RTP #i 62 catheter occlusion 62 Iloperidone 62 optimal dosing regimens 62 miconazole Lauriad ® 62 HCV protease inhibitor 62 initiated Phase 1b 62 Nasdaq ENZN 62 Rigel R# 62 ACOMPLIA R 62 RSD# 62 Simulect 62 CYT# potent vascular disrupting 62 Vilazodone 62 GVAX R 62 TASKi3 62 IAP inhibitors 62 ITAX 62 macitentan 62 FDA APPROVES 62 Ofatumumab 62 ACCLAIM II 62 EnzymeRx 62 pseudobulbar affect PBA 62 Amrubicin 62 Zavesca R 62 cilengitide 62 Cloretazine 62 PREOS R 62 Sprycel dasatinib 62 treatment naïve genotype 62 initiate Phase IIa 62 PEGINTRON TM 62 RhuDex R 62 SILENOR 62 Marketing Authorisation Application 62 Chemophase 62 ORENCIA ® 62 Completes Patient Enrolment 62 Golimumab 62 μg dose 62 Peginterferon alfa 2b 62 Evoltra TM 62 Demonstrates Significant 62 desvenlafaxine succinate 62 heavily pretreated 62 Aptivus ® 62 Phase 2b kidney transplant 62 Q#IR 62 cardio renal 62 clinical trials SGN 62 aripiprazole Abilify 62 orally dosed 62 Hyphanox 62 KNS # 62 Syncria 62 CAMPATH 62 sodium thiosulfate STS 62 personalized dendritic cell 62 ADAGIO study 62 Shigamabs ® 62 Omnitarg 62 novel histone deacetylase 62 oncolytic virus therapies 62 MYDICAR 62 angiogenesis inhibitor 62 Multiple Ascending Dose 62 ISTODAX 62 CIMZIA TM 62 INCB# [003] 62 generation URAT1 inhibitor 62 VITAL Trial 62 resminostat 62 GAMMAGARD LIQUID 62 hour bronchodilation 62 prucalopride 62 crizotinib PF # 62 DMAG 62 Relovair 62 abiraterone acetate 62 CLIRS trial 62 RGB # 62 Solazed 62 Oncotype DX colon cancer 62 systemic RNAi therapeutic 62 lenalidomide Revlimid R 62 ANTEGREN 62 SAR# [002] 62 ganaxolone 62 Pralatrexate 62 Denufosol 62 bendamustine 62 pharmacokinetic PK 62 CA4P 62 CRx 62 investigational pan BCR 62 IgG1 monoclonal antibody 62 peginesatide 62 Phase IIB clinical 62 VELCADE melphalan 62 Synavive 62 double blinded placebo 62 Completes Enrollment 62 BiTE R 62 LCP Tacro 62 sorafenib tablets 62 eritoran 62 Troxatyl TM 62 phase IIb III 62 Presents Positive 62 REBETOL combination therapy 62 AVONEX ® 62 Oral NKTR 62 P#X# antagonist 62 CRTX 62 NASDAQ REGN 62 REG1 Anticoagulation System 62 SinuNase 62 herpetic keratitis 62 Files Investigational 61 SYMMETRY trial 61 Cinryze ™ 61 refractory APL 61 Vernakalant 61 PRIMO CABG2 61 OncoVEX GM CSF 61 Vion Pharmaceuticals 61 Investigational Compound 61 6R BH4 61 systemic ALCL 61 palifosfamide Zymafos TM 61 ABSORB trial 61 PEG Interferon lambda 61 lupus nephritis 61 Phase 2b monotherapy 61 Initiates Clinical Trial 61 Presents Positive Preclinical 61 BrachySil TM 61 Versartis 61 BEMA Granisetron 61 Tamibarotene 61 lixisenatide 61 romazarit 61 solanezumab 61 oral cladribine 61 Circ Pharma 61 CALAA 61 Allovectin 7 r 61 Veronate 61 Guanilib 61 Æterna Zentaris 61 FOLFOX6 chemotherapy regimen 61 LE DT 61 Investigational Oral 61 unblinding 61 Initiates Phase 61 EDEMA4 61 ThermoDox ® clinical 61 preclinical efficacy 61 Dr. McHutchison 61 Clinical Trial Results 61 Board DSMB 61 oral proteasome inhibitor 61 initiate Phase Ib 61 phase III isavuconazole 61 investigational immunotherapy 61 Insulin PH# 61 NUVIGIL 61 NEBIDO R 61 thetreatment 61 Serdaxin ® 61 ApoB SNALP 61 multicenter Phase III 61 IMPACT IMmunotherapy 61 investigational HCV polymerase 61 Elocalcitol 61 davalintide 61 Thiarabine 61 ongoing Phase 1b 61 ALN HPN 61 Xelox 61 rNAPc2 61 Initiates Phase 2b 61 CORT # 61 epigenetic therapies 61 Nasdaq PGNX today 61 dependent kinase inhibitor 61 IPL# 61 Amigal TM 61 please visit www.advaxis.com 61 betrixaban 61 recurrent glioblastoma 61 labial herpes 61 NATRECOR R 61 Arqule 61 Velcade bortezomib 61 Ron Bentsur 61 romidepsin novel 61 trastuzumab emtansine T DM1 61 mRCC 61 relapsed multiple myeloma 61 telomerase therapeutic 61 Technosphere Insulin